Findings seen in older patients with breast cancer; non-Hispanic Black patients also less likely to have timely initiation of treatment<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Oct. 29, 2024 (HealthDay News) — For older patients with breast cancer, non-Hispanic Black race is associated with increased odds of not receiving guideline-concordant care (GCC) and less timely initiation of treatment, according to a study published online Oct. 24 in JAMA Network Open<\/em>.<\/p>\n Brenda S. Castillo, M.D., from the University of Pennsylvania in Philadelphia, and colleagues conducted a cohort study using data from the National Cancer Database for patients aged 65 years and older with stage I to III breast cancer, diagnosed between 2010 and 2019, to examine whether rates of GCC differed by race. The analytic cohort included 258,531 participants: 9.7 percent identified as non-Hispanic Black and 90.3 percent as non-Hispanic White.<\/p>\n The researchers found that 18.1 and 15.2 percent of non-Hispanic Black and non-Hispanic White participants, respectively, did not receive GCC. In the multivariate analysis, the odds of not receiving GCC were increased for non-Hispanic Black versus non-Hispanic White race (adjusted odds ratio, 1.13). In the univariate analysis, the risk for all-cause mortality was increased 26.1 percent in association with non-Hispanic Black race; after adjustment for GCC and clinical and sociodemographic factors, this percentage was attenuated to 4.7 percent (adjusted hazard ratio, 1.05). Compared with non-Hispanic Black race, non-Hispanic White race was associated with increased odds of initiating treatment within 30, 60, and 90 days of diagnosis (odds ratios, 1.65, 2.11, and 2.39, respectively).<\/p>\n “Optimizing timely receipt of GCC may improve inferior survival outcomes among non-Hispanic Black older adults with breast cancer,” the authors write.<\/p>\n